Nelfinavir

This classification denotes a protease inhibitor with the molecular formula C32H45N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HO3OGH5D7I, chemically known as 3-isoquinolinecarboxamide, n-(1,1-dimethylethyl)decahydro-2-((2r,3r)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3s,4as,8as)- but generally known as nelfinavir, which bears US NIH Compound Identifier 64143. European Medicines Agency schedules Nelfinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09186MIG. The term NELFINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). World Health Organization schedules nelfinavir in its Anatomical Therapeutic Chemical (ATC) Classification. NELFINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nelfinavir under HS 29334990 and SITC 51575. As of Q4 2014, NELFINAVIR remains the US FDA Preferred Term for this commodity. Nelfinavir bears US NLM identifiers UMLS ID C0525005 and NCI Concept Code C29285. SMILES: S(CC(NC(=O)c1c(c(O)ccc1)C)C(O)CN1CC2C(CC1C(=O)NC(C)(C)C)CCCC2)c1ccccc1.